Johnson & Johnson enters the back half of May with fresh analyst momentum but a stock that has given back 6% over the past month — a tension that sets up an interesting read on where the market is willing to take a $224 name.
The clearest catalyst this week is an upgrade from Leerink Partners. David Risinger moved to Outperform from Market Perform on May 13, setting a $265 target — nearly 18% above the current price. The timing matters: JNJ reported a solid Q1 in April, with revenue up almost 10% year-on-year to $24.1bn and an EBITDA margin above 35%. The Leerink move slots into a broader pattern of upward target revisions since that print. Morgan Stanley raised its target to $267 and Wells Fargo pushed to $263, both maintaining Overweight. Barclays and Stifel lifted targets to $255 and $250 respectively, even while sitting at neutral ratings. The Street consensus points to a mean target of roughly $253, implying about 13% return potential from here. Bulls point to MedTech and Vision division momentum, the planned Ortho separation in 2027, and growth optionality in Asia Pacific. Bears flag the talc litigation overhang and looming drug exclusivity losses as persistent drags.
Short interest at just under 1% of the free float is not a crowded story. What is notable is the pace of the move: short positions jumped 17.5% over the past week, lifting estimated shares short to around 22.8 million. That is still well below the mid-April peak near 23.5 million, but the recovery from the post-earnings fade is sharp. Cost to borrow climbed 27% over the week to 0.46%, though in absolute terms that remains cheap. Availability is abundant — the lending pool is nowhere near tight, and utilization is running at just 0.4%, far below the 52-week high of 1.01%. The short-score edged up to 30.4, its highest reading in the 10-day history in the data, but at that level it reflects modest rather than elevated bearish conviction. The RSI14 is at 40, nudging toward oversold territory, which contextualises the week's 1.3% bounce on Tuesday against a month that has been broadly weak.
Options positioning is mildly bullish. The put/call ratio dipped to 0.82 — below its 20-day average of 0.86 — and the z-score of -0.70 tells a story of call flow slightly outpacing puts relative to recent norms. It is not an aggressive directional bet, but it does not suggest the same defensive hedging seen in late April, when the PCR briefly touched 0.95. The 52-week PCR range of 0.68 to 1.13 puts the current reading closer to the bullish end of the spectrum.
Institutional flows are broadly supportive. Vanguard holds 10.1% of shares and added 3.1 million shares in the most recent reported quarter. BlackRock added 4 million shares, JP Morgan Asset Management added 3.8 million, and Capital Research made the most significant addition — building its stake by 13.3 million shares. The only notable trim among the top holders came from Morgan Stanley, which cut by 2.1 million shares. On the insider side, the 90-day picture is dominated by sales — CFO Joseph Wolk sold over $10.7 million in February, with several other executive vice presidents also reducing positions. Net insider activity over 90 days reflects a net award of shares, but the cash transactions run heavily toward selling. That is not unusual for a large-cap with active equity compensation programmes, but it adds a minor note of caution to the otherwise constructive institutional picture.
The next earnings date is July 14. Recent prints have not generated dramatic moves — Q1 produced a single-day gain of just 0.6% and a 5-day move of 1.7%, while the Q4 result in April was similarly muted with a sub-1% day-one reaction. What to watch between now and then is whether the renewed short position rebuilds further or stabilises, and whether the Leerink upgrade prompts other neutral-rated analysts to revisit targets as the stock tests the gap between current prices and a consensus that now clusters firmly in the $250s.
See the live data behind this article on ORTEX.
Open JNJ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
